Stockscreener 앱 받기
5.29
3.47%
-0.19
시장 영업 전:
4.98
-0.31
-5.86%
Replimune Group Inc 주식(REPL)의 최신 뉴스
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 22, 2025 Deadline - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL - GlobeNewswire Inc.
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - PR Newswire
Key resistance and support levels for Replimune Group Inc.Downside Risk Evaluation and Stock Analysis - Newser
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - MarketScreener
Visualizing Replimune Group Inc. stock with heatmapsEntry Timing with Downside Risk Analysis - Newser
Securities Lawsuit Alert: Replimune Group, Inc. (REPL) InvestorsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Shareholders of Replimune Group, Inc. Should Contact Levi & - GlobeNewswire
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - PR Newswire
Replimune Group Reports Increased Losses Amid Rising R&D Costs - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Stockhouse
Replimune Group, Inc. Sued for Securities Law Violations - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, - GlobeNewswire
Replimune Group (REPL) Reports Wider-than-Expected Quarterly Los - GuruFocus
Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact The Gross Law Firm about pending Class ActionREPL - WV News
Replimune Reports Fiscal First Quarter 2026 Financial Results an - GuruFocus
Biotech Replimune's Q1 net loss widens, cash balance drops - MarketScreener
Replimune Group, Inc. SEC 10-Q Report - TradingView
Replimune's Melanoma Drug Hits FDA Roadblock: Q1 Losses Widen to $86.7M as Clinical Trials Advance - Stock Titan
Replimune Group (REPL) Expected to Announce Earnings on Thursday - Defense World
Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
Securities Fraud Class Action Filed Against Replimune Group, Inc. (REPL)Levi & Korsinsky Reminds Investors of September 22, 2025 - ACCESS Newswire
REPL DEADLINE: Replimune Group Investors Should Contact - GlobeNewswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - PR Newswire
Shareholders who lost money on Replimune Group, Inc. - GlobeNewswire
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Newsfile
The researchers who designed Replimune's melanoma drug study offer a rare, detailed protest of the FDA's CRL - Endpoints News
Replimune Group, Inc. Stockholders With Large Losses Should Contact Robbins LLP For Information About Leading The REPL Class Action Lawsuit - ACCESS Newswire
Securities Lawsuit Alert: Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Why Is Replimune Stock Trading Lower On Monday? - Benzinga
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Replimune Shares Slide as FDA Dispute Over Cancer Drug Approval Comes to Light - MSN
Replimune’s Turmoil: What Comes Next? - StocksToTrade
REPL Stock Drops: A Closer Look - timothysykes.com
Replimune stock plunges after FDA cancer drug rejection details emerge By Investing.com - Investing.com Nigeria
Replimune stock plunges after FDA cancer drug rejection details emerge - Investing.com
REPL LAWSUIT ALERT: The Gross Law Firm Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
Replimune stock down after report on drug rejection (REPL) - Seeking Alpha
Advanced analytics toolkit walkthrough for Replimune Group Inc.Chart Confirmation Setup with ROI Signals - Newser
Can trapped investors hope for a rebound in Replimune Group Inc.Free Triple Digit Growth Focused Trade Plan - Newser
Navigating the Fallout: Replimune's FDA Hurdle and the Road to Investor Recovery - AInvest
Replimune Group (REPL.O) Sees Sharp Intraday Move—Here’s Why - AInvest
Bragar Eagel & Squire, P.C. Is Reminds Investors of Class - GlobeNewswire
Join Class Action to Recover Losses from Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent
Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st
Replimune Group, Inc. Investors: Join Class Action Suit for Securities Fraud Recovery - AInvest
Lost Money on Replimune Group, Inc.(REPL)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - MarketScreener
Important Notice to Long-Term Shareholders of Centene - GlobeNewswire
Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector - Stocktwits
Biotech Stocks To Follow Today – July 30th - Defense World
Traders Buy Large Volume of Call Options on Replimune Group (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Raised to Overweight at Cantor Fitzgerald - Defense World
0.24%
3.39%
자본화:
|
볼륨(24시간):